What is the clinical evidence from this study?

Study design: Other. Population: Insulin resistance (n=13). Intervention: Troglitazone vs. Baseline / Normal subjects. Primary outcome: Flow-mediated dilatation (FMD) of the brachial artery.

What does this research mean for the field?

Troglitazone administration for 4 weeks significantly improves flow-mediated dilatation of the brachial artery and reduces the insulin response in non-diabetic men with insulin resistance. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate whether improving insulin sensitivity with troglitazone ameliorates endothelial dysfunction in non-diabetic individuals with insulin resistance.

January 1, 2000Journal of Atherosclerosis and ThrombosisOpen Access

Troglitazone Improves Endothelial Dysfunction in Patients with Insulin Resistance

View Full Paper

Ask AI

Bookmark

Key result

Troglitazone 400 mg twice daily for 4 weeks significantly improved flow-mediated dilatation of the brachial artery and reduced insulin response in non-diabetic men with insulin resistance.

Why the study?

Does troglitazone improve flow-mediated dilatation in non-diabetic male subjects with insulin resistance?

Population

13 non-diabetic male subjects, including 7 with hyperinsulinemic response to oral glucose load and 6 normal…

Comparison

Troglitazone 400 mg administered for 4 weeks vs Baseline and normal subjects

Design

Cohort

Follow-up

4 weeks

Authors

YWYoshirô WatanabeOcean University of China SSSatoshi SunayamaShowa University KSKazunori ShimadaKanazawa University

Discussion

Member takes

Implication

Supports endothelial benefits of troglitazone in insulin-resistant men without diabetes; hypothesis-generating and should not change practice.

Key Points

To investigate whether improving insulin sensitivity with troglitazone ameliorates endothelial dysfunction in non-diabetic individuals with insulin resistance.
Studied 13 non-diabetic male subjects categorized into an insulin-resistant group with hyperinsulinemic response to oral glucose (n=7) and normal controls (n=6).
Administered troglitazone at 400 mg daily for 4 weeks.
Measured brachial artery flow-mediated dilatation (FMD) via high-resolution ultrasonography alongside glucose and insulin responses during oral glucose tolerance testing before and after treatment.
In insulin-resistant subjects, fasting glucose significantly decreased from 4.9±0.3 to 4.7±0.3 mmol/L (p<0.05) and fasting insulin decreased from 45±30 to 25±15 pmol/L (p<0.05).
Oral glucose load responses improved significantly, reducing glucose AUC from 15.0±3.5 to 13.0±2.2 mmol·h/L (p<0.05) and insulin AUC from 965±560 to 475±275 pmol·h/L (p<0.05).
Flow-mediated dilatation significantly improved following troglitazone treatment, showing a significant inverse correlation with insulin AUC (r=-0.64, p<0.05).

Structured PICO

Does troglitazone improve flow-mediated dilatation in non-diabetic male subjects with insulin resistance?

Population

13 non-diabetic male subjects, including 7 with hyperinsulinemic response to oral glucose load (insulin resistant) and 6 normal subjects

Intervention

Troglitazone 400 mg administered for 4 weeks

Comparator

Baseline (before administration) and normal subjects

Outcome

Flow-mediated dilatation (FMD) of the brachial artery examined by high resolution ultrasonographysurrogate

Troglitazone improves endothelial dysfunction and insulin response in non-diabetic men with insulin resistance, suggesting a potential role in preventing atherosclerosis.

Limitations

Small sample size
Only male subjects included
Cannot exclude direct antioxidant effects of troglitazone on endothelial function
Cannot specify the exact mechanism of improvement

Cite This Study

Watanabe et al. (2000) studied Insulin resistance (n=13). Troglitazone vs. Baseline / Normal subjects was evaluated on Flow-mediated dilatation (FMD) of the brachial artery. Troglitazone 400 mg twice daily for 4 weeks significantly improved flow-mediated dilatation of the brachial artery and reduced insulin response in non-diabetic men with insulin resistance.

synapsesocial.com/papers/6a1c851aecffbcc5fca17203 https://doi.org/10.5551/jat1994.7.159

View Full Paper

Ask AI

Bookmark

Implication

Supports endothelial benefits of troglitazone in insulin-resistant men without diabetes; hypothesis-generating and should not change practice.

Troglitazone Improves Endothelial Dysfunction in Patients with Insulin Resistance

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Troglitazone Improves Endothelial Dysfunction in Patients with Insulin Resistance

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider